Compare Nike Inc (NKE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Sana Biotechnology Inc — how do they compare? Nike Inc trades at $40.7 (market cap $61.30B), while Sana Biotechnology Inc trades at $3.74 (market cap $1.13B). The key difference: Nike Inc is far larger — about 54.2× Sana Biotechnology Inc's market cap, and Nike Inc pays a 3.97% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NKE | SANA | |
|---|---|---|
Market Cap | $61.30B | $1.13B |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $79.17 | $5.92 |
52-Week Low | $40.51 | $2.68 |
Enterprise Value | $63.30B | $1.05B |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $41.32, down 1.88% on the day, reflecting ongoing investor caution amid revenue declines and margin pressures. Recent earnings beats have not offset concerns over sales weakness in key markets like China. Technical indicators are bearish, with the stock testing support near $41. The company maintains strong brand equity but faces execution risks in its turnaround strategy.
The outlook hinges on Nike's ability to stabilize revenue and improve margins through its 'Win Now' initiatives. Near-term catalysts include the Q4 2026 earnings report on June 30, 2026. Risks include persistent demand softness and competitive pressures, while the consensus price target of $50.45 suggests 22% upside if execution improves.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
